# Lipids in kidney diseases: from systemic imbalance to intrarenal alterations of cellular lipid metabolism in rare and common kidney diseases

**Authors:** Carola Garavaglia, Alice Ossoli, Monica Gomaraschi

PMC · DOI: 10.1007/s00109-026-02654-0 · Journal of Molecular Medicine (Berlin, Germany) · 2026-02-20

## TL;DR

This paper explores how lipid imbalances contribute to kidney disease, affecting both rare and common forms of chronic kidney disease.

## Contribution

The paper provides a novel overview of how systemic and intrarenal lipid metabolism alterations contribute to kidney disease progression.

## Key findings

- Lipotoxicity plays a key role in both metabolic and non-metabolic chronic kidney disease.
- Lipid accumulation in renal cells affects cell viability and function through multiple signaling pathways.
- Correcting systemic or local lipid imbalances may offer new approaches for managing CKD.

## Abstract

Chronic kidney disease (CKD) is expected to be the fifth cause of global mortality by 2040. Modifiable and non-modifiable risk factors for CKD range from metabolic conditions, such as diabetes or obesity, to genetic defects. Regardless of the triggering factor, irreversible injury and loss of kidney cells result in the decline of kidney function. Renal damage often occurs through common signaling pathways promoting inflammation, oxidative stress, organelle dysfunction, complement activation, apoptosis, and fibrogenesis. Lipotoxicity is emerging as a key player in CKD of both metabolic and non-metabolic origin. Here, we provide an overview of the mechanisms beyond renal lipid accumulation in CKD, ranging from systemic imbalance of lipid/lipoprotein metabolism to alterations of cell lipid uptake, synthesis, and disposal. Moreover, the impact of lipid accumulation in glomerular and tubular cells is addressed. Several lipid species were shown to accumulate in renal cells, from cholesterol and fatty acids to sphingolipids; they can affect cell viability and function not only as structural components of biological membranes or energetic substrates but also as bioactive molecules able to modulate multiple signaling pathways. The possible role of established and novel approaches to correct systemic or local lipid imbalance in the management of CKD is discussed.

## Linked entities

- **Chemicals:** cholesterol (PubChem CID 5997), fatty acids (PubChem CID 264)
- **Diseases:** chronic kidney disease (MONDO:0005300), diabetes (MONDO:0005015), obesity (MONDO:0011122)

## Full-text entities

- **Genes:** PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, TFEB (transcription factor EB) [NCBI Gene 7942] {aka ALPHATFEB, BHLHE35, TCFEB}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, MIR802 (microRNA 802) [NCBI Gene 768219] {aka MIRN802, hsa-mir-802}, PRKAB1 (protein kinase AMP-activated non-catalytic subunit beta 1) [NCBI Gene 5564] {aka AMPK, HAMPKb}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, ASAH1 (N-acylsphingosine amidohydrolase 1) [NCBI Gene 427] {aka AC, ACDase, ASAH, PHP, PHP32, SMAPME}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, ACLY (ATP citrate lyase) [NCBI Gene 47] {aka ACL, ATPCL, CLATP}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, NPC1 (NPC intracellular cholesterol transporter 1) [NCBI Gene 4864] {aka NPC, POGZ, SLC65A1}, LCAT (lecithin-cholesterol acyltransferase) [NCBI Gene 3931], C3AR1 (complement C3a receptor 1) [NCBI Gene 719] {aka AZ3B, C3AR, HNFAG09}, GLA (galactosidase alpha) [NCBI Gene 2717] {aka GALA}, C3 (complement C3) [NCBI Gene 718] {aka AHUS5, ARMD9, ASP, C3a, C3b, CPAMD1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, COL4A3 (collagen type IV alpha 3 chain) [NCBI Gene 1285] {aka ATS2, ATS3, ATS3A, ATS3B, BFH2}, NOX4 (NADPH oxidase 4) [NCBI Gene 50507] {aka KOX, KOX-1, RENOX}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, TLR2 (toll like receptor 2) [NCBI Gene 7097] {aka CD282, TIL4}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, NPC2 (NPC intracellular cholesterol transporter 2) [NCBI Gene 10577] {aka EDDM1, HE1}, PKD1 (polycystin 1, transient receptor potential channel interacting) [NCBI Gene 5310] {aka PBP, PC1, Pc-1, TRPP1, eliosin}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, DNASE2 (deoxyribonuclease 2, lysosomal) [NCBI Gene 1777] {aka AIPCS, DNASE2A, DNL, DNL2}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, COL4A5 (collagen type IV alpha 5 chain) [NCBI Gene 1287] {aka ASLN, ATS, ATS1, CA54}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21}, SREBF2 (sterol regulatory element binding transcription factor 2) [NCBI Gene 6721] {aka SREBP-2, SREBP2, bHLHd2}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MMRN1 (multimerin 1) [NCBI Gene 22915] {aka ECM, EMILIN4, GPIa*, MMRN}, HBHR (alpha-thalassemia/mental retardation syndrome, type 1) [NCBI Gene 8129] {aka ATR1}, CNBP (CCHC-type zinc finger nucleic acid binding protein) [NCBI Gene 7555] {aka CNBP1, DM2, PROMM, RNF163, ZCCHC22, ZNF9}, CXCR6 (C-X-C motif chemokine receptor 6) [NCBI Gene 10663] {aka BONZO, CD186, CDw186, STRL33, TYMSTR}, APOL1 (apolipoprotein L1) [NCBI Gene 8542] {aka APO-L, APOL, APOL-I, FSGS4}, EPO (erythropoietin) [NCBI Gene 2056] {aka DBAL, ECYT5, EP, MVCD2}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, LIPA (lipase A, lysosomal acid type) [NCBI Gene 3988] {aka CESD, LAL}, SMPD1 (sphingomyelin phosphodiesterase 1) [NCBI Gene 6609] {aka ASM, ASMASE, NPD}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, SLC5A2 (solute carrier family 5 member 2) [NCBI Gene 6524] {aka SGLT2}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, C5AR1 (complement C5a receptor 1) [NCBI Gene 728] {aka C5A, C5AR, C5R1, CD88}, PKD2 (polycystin 2, transient receptor potential cation channel) [NCBI Gene 5311] {aka APKD2, PC2, PKD4, Pc-2, TRPP2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, SLC27A2 (solute carrier family 27 member 2) [NCBI Gene 11001] {aka ACSVL1, FACVL1, FATP2, HsT17226, VLACS, VLCS}, NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971] {aka BAR, FXR, HRR-1, HRR1, PFIC5, RIP14}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, SOAT1 (sterol O-acyltransferase 1) [NCBI Gene 6646] {aka ACACT, ACAT, ACAT-1, ACAT1, SOAT, STAT}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, COL4A4 (collagen type IV alpha 4 chain) [NCBI Gene 1286] {aka ATS2, BFH, BFH1, CA44}, AGT (angiotensinogen) [NCBI Gene 183] {aka ANHU, SERPINA8, hFLT1}, ABCB6 (ATP binding cassette subfamily B member 6 (LAN blood group)) [NCBI Gene 10058] {aka ABC, LAN, MTABC3, PRP, umat}
- **Diseases:** sudden cardiac death (MESH:D016757), overweight (MESH:D050177), apoE deficiency (MESH:C566260), acute and chronic kidney diseases (MESH:D058186), Gaucher disease (MESH:D005776), function (MESH:D003291), hypoxic (MESH:D002534), obese (MESH:D009765), arrhythmia (MESH:D001145), Niemann-Pick disease (MESH:D009542), organ dysfunction (MESH:D009102), LPG (MESH:C567089), FSGS (MESH:D005923), developmental defects (MESH:D000094602), tubulointerstitial (MESH:D009395), Hypoxia (MESH:D000860), bone demineralization (MESH:D018488), loss of muscle mass (MESH:C536030), NPC (MESH:D052556), Farber disease (MESH:D055577), decline of kidney function (MESH:D007680), IgA nephropathy (MESH:D005922), Proteinuria (MESH:D011507), autosomal dominant disease (MESH:D030342), metabolic diseases (MESH:D008659), renal (MESH:D006030), familial type III hyperlipidemia (MESH:D006950), Mitochondrial dysfunction (MESH:D028361), nephrotic syndrome (MESH:D009404), Diabetic dyslipidemia (MESH:D050171), TEC (MESH:C536980), Niemann-Pick Disease type A or B (MESH:D052537), expansion (OMIM:616452), LCAT deficiency (MESH:D007863), hyperglycemia (MESH:D006943), metabolic syndrome (MESH:D024821), vascular rarefaction (MESH:D000073436), Fibrosis (MESH:D005355), type III hyperlipidemia (MESH:D006949), Chronic inflammation (MESH:D007249), injury (MESH:D014947), atrophy (MESH:D001284), CKD (MESH:D051436), Fabry disease (MESH:D000795), LSD (MESH:D016464), FATP (MESH:C536830), lupus nephritis (MESH:D008181), Diabetic (MESH:D003920), ALGS (MESH:D016738), ischemic and (MESH:D002545), renal failure (MESH:D051437), organelle dysfunction (MESH:D006331), autosomal recessive neurovisceral disease (MESH:D052536), Renal disease (MESH:D007674), hypercholesterolemia (MESH:D006937), Mucolipidosis II and III (MESH:D009081), Hypertriglyceridemia (MESH:D015228), chronic (MESH:D002908), tissue injury (MESH:D017695), renal cell death (MESH:D002292)
- **Chemicals:** streptozotocin (MESH:D013311), empagliflozin (MESH:C570240), Acetyl-CoA (MESH:D000105), FFAs (MESH:D005230), Metformin (MESH:D008687), glucocerebroside (MESH:D005963), PL (MESH:D010743), ceramide (MESH:D002518), galactose (MESH:D005690), INT-767 (MESH:C000602622), Cholesterol (MESH:D002784), Oxysterols (MESH:D000072376), glycolipid (MESH:D006017), oxygen (MESH:D010100), stearate (MESH:D013228), salt (MESH:D012492), TGs (MESH:C026285), mevalonate (MESH:D008798), fat (MESH:D005223), mannose-6-phosphate (MESH:C027693), Tricarboxylic acid (MESH:D014233), carbon (MESH:D002244), Aldosterone (MESH:D000450), TG (MESH:D014280), glycosphingolipid (MESH:D006028), n-3 polyunsaturated FAs (MESH:D015525), obeticholic acid (MESH:C464660), lyso-SM (MESH:C005356), Lipid (MESH:D008055), fibrates (MESH:D058607), steroid hormones (MESH:D013256), citrate (MESH:D019343), ATP (MESH:D000255), sphingosine (MESH:D013110), calcium (MESH:D002118), ROS (MESH:D017382), phosphorylcholine (MESH:D010767), glucose (MESH:D005947), sphingolipid (MESH:D013107), sodium (MESH:D012964), potassium (MESH:D011188), unsaturated FAs (MESH:D005231), SM (MESH:D013109), palmitate (MESH:D010168), LDL-C (-), FA (MESH:D005227), CE (MESH:D002788), globotriaosylceramide (MESH:C018549), TCA (MESH:D014238), bempedoic acid (MESH:C581236)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** Ito K, Cys74Tyr, Eto Y

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12920394/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12920394/full.md

## References

128 references — full list in the complete paper: https://tomesphere.com/paper/PMC12920394/full.md

---
Source: https://tomesphere.com/paper/PMC12920394